@article{ART001100047,
author={이의연 and 박시영 and 송현석 and 손명진 and 이규양 and 유성은 and 김영진},
title={KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis},
journal={Experimental and Molecular Medicine},
issn={1226-3613},
year={2006},
volume={38},
number={5},
pages={502-508}
}

TY - JOUR
AU - 이의연
AU - 박시영
AU - 송현석
AU - 손명진
AU - 이규양
AU - 유성은
AU - 김영진
TI - KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
T2 - Experimental and Molecular Medicine
JO - Experimental and Molecular Medicine
PY - 2006
VL - 38
IS - 5
PB - 생화학분자생물학회
SP - 502
EP - 508
SN - 1226-3613
AB - Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angio-genesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new ben-zopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogene-sis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
KW - angiogenesis; angiogenesis inhibitors; fi-broblast growth factor 2; neoplasms
DO -
UR -
ER -

이의연, 박시영, 송현석, 손명진, 이규양, 유성은 and 김영진. 2006, "KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis", Experimental and Molecular Medicine, vol.38, no.5 pp.502-508.

이의연, 박시영, 송현석, 손명진, 이규양, 유성은, 김영진 "KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis" Experimental and Molecular Medicine 38.5 pp.502-508 (2006) : 502.

이의연, 박시영, 송현석, 손명진, 이규양, 유성은, 김영진. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. 2006; 38(5), 502-508.

이의연, 박시영, 송현석, 손명진, 이규양, 유성은 and 김영진. "KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis" Experimental and Molecular Medicine 38, no.5 (2006) : 502-508.

이의연; 박시영; 송현석; 손명진; 이규양; 유성은; 김영진. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. Experimental and Molecular Medicine, 38(5), 502-508.

이의연; 박시영; 송현석; 손명진; 이규양; 유성은; 김영진. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. Experimental and Molecular Medicine. 2006; 38(5) 502-508.

이의연, 박시영, 송현석, 손명진, 이규양, 유성은, 김영진. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. 2006; 38(5), 502-508.

이의연, 박시영, 송현석, 손명진, 이규양, 유성은 and 김영진. "KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis" Experimental and Molecular Medicine 38, no.5 (2006) : 502-508.